1
|
Suárez-García S, Arias-Ramos N, Frias C, Candiota AP, Arús C, Lorenzo J, Ruiz-Molina D, Novio F. Dual T 1/ T 2 Nanoscale Coordination Polymers as Novel Contrast Agents for MRI: A Preclinical Study for Brain Tumor. ACS Appl Mater Interfaces 2018; 10:38819-38832. [PMID: 30351897 DOI: 10.1021/acsami.8b15594] [Citation(s) in RCA: 39] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/14/2023]
Abstract
In the last years, extensive attention has been paid on designing and developing functional imaging contrast agents for providing accurate noninvasive evaluation of pathology in vivo. However, the issue of false-positives or ambiguous imaging and the lack of a robust strategy for simultaneous dual-mode imaging remain to be fully addressed. One effective strategy for improving it is to rationally design magnetic resonance imaging (MRI) contrast agents (CAs) with intrinsic T1/ T2 dual-mode imaging features. In this work, the development and characterization of one-pot synthesized nanostructured coordination polymers (NCPs) which exhibit dual mode T1/ T2 MRI contrast behavior is described. The resulting material comprises the combination of different paramagnetic ions (Fe3+, Gd3+, Mn2+) with selected organic ligands able to induce the polymerization process and nanostructure stabilization. Among them, the Fe-based NCPs showed the best features in terms of colloidal stability, low toxicity, and dual T1/ T2 MRI contrast performance overcoming the main drawbacks of reported CAs. The dual-mode CA capability was evaluated by different means: in vitro phantoms, ex vivo and in vivo MRI, using a preclinical model of murine glioblastoma. Interestingly, the in vivo MRI of Fe-NCPs show T1 and T2 high contrast potential, allowing simultaneous recording of positive and negative contrast images in a very short period of time while being safer for the mouse. Moreover, the biodistribution assays reveals the persistence of the nanoparticles in the tumor and subsequent gradual clearance denoting their biodegradability. After a comparative study with commercial CAs, the results suggest these nanoplatforms as promising candidates for the development of dual-mode MRI CAs with clear advantages.
Collapse
Affiliation(s)
- S Suárez-García
- Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and BIST , Campus UAB, Bellaterra , 08193 Barcelona , Spain
| | - N Arias-Ramos
- Departament de Bioquímica i Biologia Molecular , Universitat Autònoma de Barcelona , 08193 Cerdanyola del Vallès , Spain
- Centro de Investigación Biomédica en Red: Bioingeniería, Biomateriales y Nanomedicina , 08193 Cerdanyola del Vallès , Spain
| | - C Frias
- Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and BIST , Campus UAB, Bellaterra , 08193 Barcelona , Spain
| | - A P Candiota
- Departament de Bioquímica i Biologia Molecular , Universitat Autònoma de Barcelona , 08193 Cerdanyola del Vallès , Spain
- Centro de Investigación Biomédica en Red: Bioingeniería, Biomateriales y Nanomedicina , 08193 Cerdanyola del Vallès , Spain
- Institut de Biotecnologia i de Biomedicina, Departament de Bioquimica i Biologia Molecular , Universitat Autònoma de Barcelona , 08193 Cerdanyola del Vallès , Barcelona , Spain
| | - C Arús
- Departament de Bioquímica i Biologia Molecular , Universitat Autònoma de Barcelona , 08193 Cerdanyola del Vallès , Spain
- Centro de Investigación Biomédica en Red: Bioingeniería, Biomateriales y Nanomedicina , 08193 Cerdanyola del Vallès , Spain
- Institut de Biotecnologia i de Biomedicina, Departament de Bioquimica i Biologia Molecular , Universitat Autònoma de Barcelona , 08193 Cerdanyola del Vallès , Barcelona , Spain
| | - J Lorenzo
- Departament de Bioquímica i Biologia Molecular , Universitat Autònoma de Barcelona , 08193 Cerdanyola del Vallès , Spain
- Institut de Biotecnologia i de Biomedicina, Departament de Bioquimica i Biologia Molecular , Universitat Autònoma de Barcelona , 08193 Cerdanyola del Vallès , Barcelona , Spain
| | - D Ruiz-Molina
- Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and BIST , Campus UAB, Bellaterra , 08193 Barcelona , Spain
| | - F Novio
- Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and BIST , Campus UAB, Bellaterra , 08193 Barcelona , Spain
- Departament de Química , Universitat Autònoma de Barcelona , 08193 Cerdanyola del Vallès , Barcelona , Spain
| |
Collapse
|
2
|
Delgado-Goñi T, Ortega-Martorell S, Ciezka M, Olier I, Candiota AP, Julià-Sapé M, Fernández F, Pumarola M, Lisboa PJ, Arús C. MRSI-based molecular imaging of therapy response to temozolomide in preclinical glioblastoma using source analysis. NMR Biomed 2016; 29:732-743. [PMID: 27061401 DOI: 10.1002/nbm.3521] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/12/2015] [Revised: 02/14/2016] [Accepted: 02/23/2016] [Indexed: 06/05/2023]
Abstract
Characterization of glioblastoma (GB) response to treatment is a key factor for improving patients' survival and prognosis. MRI and magnetic resonance spectroscopic imaging (MRSI) provide morphologic and metabolic profiles of GB but usually fail to produce unequivocal biomarkers of response. The purpose of this work is to provide proof of concept of the ability of a semi-supervised signal source extraction methodology to produce images with robust recognition of response to temozolomide (TMZ) in a preclinical GB model. A total of 38 female C57BL/6 mice were used in this study. The semi-supervised methodology extracted the required sources from a training set consisting of MRSI grids from eight GL261 GBs treated with TMZ, and six control untreated GBs. Three different sources (normal brain parenchyma, actively proliferating GB and GB responding to treatment) were extracted and used for calculating nosologic maps representing the spatial response to treatment. These results were validated with an independent test set (7 control and 17 treated cases) and correlated with histopathology. Major differences between the responder and non-responder sources were mainly related to the resonances of mobile lipids (MLs) and polyunsaturated fatty acids in MLs (0.9, 1.3 and 2.8 ppm). Responding tumors showed significantly lower mitotic (3.3 ± 2.9 versus 14.1 ± 4.2 mitoses/field) and proliferation rates (29.8 ± 10.3 versus 57.8 ± 5.4%) than control untreated cases. The methodology described in this work is able to produce nosological images of response to TMZ in GL261 preclinical GBs and suitably correlates with the histopathological analysis of tumors. A similar strategy could be devised for monitoring response to treatment in patients. Copyright © 2016 John Wiley & Sons, Ltd.
Collapse
Affiliation(s)
- T Delgado-Goñi
- Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain
- Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain
- Division of Radiotherapy and Imaging, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
| | - S Ortega-Martorell
- Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain
- Department of Mathematics and Statistics, Liverpool John Moores University, Liverpool, UK
| | - M Ciezka
- Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain
- Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain
- Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain
| | - I Olier
- Institute for Science and Technology in Medicine, Keele University, Stoke-On-Trent, UK
- Centre for Health Informatics, Institute of Population Health University of Manchester, Manchester, UK
| | - A P Candiota
- Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain
- Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain
- Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain
| | - M Julià-Sapé
- Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain
- Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain
- Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain
| | - F Fernández
- Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain
- Departament de Medicina i Cirurgia Animals, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain
| | - M Pumarola
- Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain
- Departament de Medicina i Cirurgia Animals, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain
| | - P J Lisboa
- Department of Mathematics and Statistics, Liverpool John Moores University, Liverpool, UK
| | - C Arús
- Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain
- Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain
- Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain
| |
Collapse
|
3
|
Castells X, Acebes JJ, Majós C, Boluda S, Julià-Sapé M, Candiota AP, Ariño J, Barceló A, Arús C. Development of robust discriminant equations for assessing subtypes of glioblastoma biopsies. Br J Cancer 2012; 106:1816-25. [PMID: 22568967 PMCID: PMC3364559 DOI: 10.1038/bjc.2012.174] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Background: In the preceding decade, various studies on glioblastoma (Gb) demonstrated that
signatures obtained from gene expression microarrays correlate better with survival than
with histopathological classification. However, there is not a universal consensus
formula to predict patient survival. Methods: We developed a gene signature using the expression profile of 47 Gbs through an
unsupervised procedure and two groups were obtained. Subsequent to a training procedure
through leave-one-out cross-validation, we fitted a discriminant (linear discriminant
analysis (LDA)) equation using the four most discriminant probesets. This was repeated
for two other published signatures and the performance of LDA equations was evaluated on
an independent test set, which contained status of IDH1 mutation, EGFR
amplification, MGMT methylation and gene VEGF expression, among other
clinical and molecular information. Results: The unsupervised local signature was composed of 69 probesets and clearly defined two
Gb groups, which would agree with primary and secondary Gbs. This hypothesis was
confirmed by predicting cases from the independent data set using the equations
developed by us. The high survival group predicted by equations based on our local and
one of the published signatures contained a significantly higher percentage of cases
displaying IDH1 mutation and non-amplification of EGFR. In contrast,
only the equation based on the published signature showed in the poor survival group a
significant high percentage of cases displaying a hypothesised methylation of
MGMT gene promoter and overexpression of gene VEGF. Conclusion: We have produced a robust equation to confidently discriminate Gb subtypes based in the
normalised expression level of only four genes.
Collapse
Affiliation(s)
- X Castells
- Servei de Genòmica, Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Candiota AP, Majós C, Julià-Sapé M, Cabañas M, Acebes JJ, Moreno-Torres A, Griffiths JR, Arús C. Non-invasive grading of astrocytic tumours from the relative contents of myo-inositol and glycine measured by in vivo MRS. JBR-BTR 2011; 94:319-29. [PMID: 22338386 DOI: 10.5334/jbr-btr.698] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
MRI and MRS are established methodologies for evaluating intracranial lesions. One MR spectral feature suggested for in vivo grading of astrocytic tumours is the apparent myo-lnositol (ml) intensity (ca 3.55 ppm) at short echo times, although glycine (gly) may also contribute in vivo to this resonance. The purpose of this study was to quantitatively evaluate the ml + gly contribution to the recorded spectral pattern in vivo and correlate it with in vitro data obtained from perchloric acid extraction of tumour biopsies. Patient spectra (n = 95) at 1.5T at short (20-31 ms) and long (135-136 ms) echo times were obtained from the INTERPRET MRS database (http://gabrmn.uab.eslinterpretvalidateddbl). Phantom spectra were acquired with a comparable protocol. Spectra were automatically processed and the ratios of the (ml + gly) to Cr peak heights ((ml + gly)/Cr) calculated. Perchloric acid extracts of brain tumour biopsies were analysed by high-resolution NMR at 9.4T. The ratio (ml + gly)/Cr decreased significantly with astrocytic grade in vivo between low-grade astrocytoma (A2) and glioblastoma multiforme (GBM). In vitro results displayed a somewhat different tendency, with anaplastic astrocytomas having significantly higher (ml + gly)/Cr than A2 and GBM. The discrepancy between in vivo and in vitro data suggests that the NMR visibility of glycine in glial brain tumours is restricted in vivo.
Collapse
Affiliation(s)
- A P Candiota
- Centro de Investigación Biomédica en Red en Bioingenieria, Biomateriales y Nanomedicina (CIBER-BBN), Cerdanyola del Vallès, Spain
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Valverde D, Quintero MR, Candiota AP, Badiella L, Cabañas ME, Arús C. Analysis of the changes in the 1H NMR spectral pattern of perchloric acid extracts of C6 cells with growth. NMR Biomed 2006; 19:223-30. [PMID: 16485320 DOI: 10.1002/nbm.1024] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
The aim of this work was to identify spectral markers of cell proliferation that could be of use in clinical MRS. Cultured C6 ATCC rat glioma cells were used as models for this purpose and metabolites were extracted with perchloric acid at three different growth curve stages: log, confluence and post-confluence. 1D and 2D in vitro(1)H NMR spectra were recorded at 9.4 T. Statistically significant changes in myo-inositol and glutamine concentrations between log phase and post-confluence were found when normalized to the creatine ratio. The myo-inositol/creatine ratio was 2.76 +/- 0.82 at log phase increasing to 7.43 +/- 1.34 at post-confluence, while the glutamine/creatine ratio decreased from 0.22 +/- 0.03 to 0.10 +/- 0.02. No significant differences were recorded for other metabolites investigated. The fact that both myo-inositol and glutamine are detectable by in vivo MRS at clinical fields makes their changes relevant as potential astrocytic tumour proliferation rate markers in clinical MRS.
Collapse
Affiliation(s)
- D Valverde
- Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, Spain
| | | | | | | | | | | |
Collapse
|
6
|
Candiota AP, Majós C, Bassols A, Cabañas ME, Acebes JJ, Quintero MR, Arús C. Assignment of the 2.03 ppm resonance in in vivo 1H MRS of human brain tumour cystic fluid: contribution of macromolecules. MAGMA 2004; 17:36-46. [PMID: 15340855 DOI: 10.1007/s10334-004-0043-y] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/15/2004] [Revised: 05/04/2004] [Accepted: 05/26/2004] [Indexed: 11/29/2022]
Abstract
MRI and MRS are established techniques for the evaluation of intracranial mass lesions and cysts. The 2.03 ppm signal recorded in their (1)H-MRS spectra is often assigned to NAA from outer volume contamination, although it has also been detected in non-infiltrating tumours and large cysts. We have investigated the molecular origin of this resonance in ten samples of cystic fluids from human brain tumours. The NMR detected content of the 2.03 ppm resonance in 136 ms echo time spectra, assuming an N- CH(3) origin, was 3.19 +/- 1.01 mM. Only one third (34 +/- 12%) of the N-acetyl containing compound (NAC) signal could be extracted by perchloric acid (PCA) indicating that most of it originated in a macromolecular PCA-insoluble component. Chemical analysis of the cyst fluids showed that sialic acid bound to macromolecules would account for 64.3% and hexuronic containing compounds for 29.2% of the NMR-detectable ex vivo signal, 93.4% of the signal at TE 136 ms. Lactate content measured by NMR (6.4 +/- 4.4 mM) and the predominance of NAC originating in sialic acid point to a major origin from tumour rather than from plasma for this 2.03 ppm resonance.
Collapse
Affiliation(s)
- A P Candiota
- Departament de Bioquímica i Biologia Molecular, Unitat de Bioquímica de Ciències Edifici Cs, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, Spain
| | | | | | | | | | | | | |
Collapse
|